Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 25206276)

  • 1. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
    To KK; Tong CW; Wu M; Cho WC
    World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
    Yu X; Li Z; Yu J; Chan MT; Wu WK
    Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives.
    Muhammad S; Kaur K; Huang R; Zhang Q; Kaur P; Yazdani HO; Bilal MU; Zheng J; Zheng L; Wang XS
    World J Gastroenterol; 2014 Dec; 20(45):17011-9. PubMed ID: 25493013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs targeting EGFR signalling pathway in colorectal cancer.
    Mlcochova J; Faltejskova P; Nemecek R; Svoboda M; Slaby O
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1615-24. PubMed ID: 23817698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.
    De Divitiis C; Nasti G; Montano M; Fisichella R; Iaffaioli RV; Berretta M
    World J Gastroenterol; 2014 Nov; 20(41):15049-59. PubMed ID: 25386053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Coppedè F; Lopomo A; Spisni R; Migliore L
    World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.
    Ragusa M; Majorana A; Statello L; Maugeri M; Salito L; Barbagallo D; Guglielmino MR; Duro LR; Angelica R; Caltabiano R; Biondi A; Di Vita M; Privitera G; Scalia M; Cappellani A; Vasquez E; Lanzafame S; Basile F; Di Pietro C; Purrello M
    Mol Cancer Ther; 2010 Dec; 9(12):3396-409. PubMed ID: 20881268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dual Role of MicroRNAs in Colorectal Cancer Progression.
    Ding L; Lan Z; Xiong X; Ao H; Feng Y; Gu H; Yu M; Cui Q
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30227605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of targeted agents in metastatic colorectal cancer.
    Prenen H; Vecchione L; Van Cutsem E
    Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
    Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
    Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
    Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.
    Xie T; Huang M; Wang Y; Wang L; Chen C; Chu X
    Cell Physiol Biochem; 2016; 40(1-2):62-76. PubMed ID: 27842308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of noncoding RNAs in colorectal cancer chemoresistance.
    Wei L; Wang X; Lv L; Zheng Y; Zhang N; Yang M
    Cell Oncol (Dordr); 2019 Dec; 42(6):757-768. PubMed ID: 31359293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Role of MicroRNAs in Colorectal Cancer].
    Kim SW
    Korean J Gastroenterol; 2017 Apr; 69(4):206-211. PubMed ID: 28449421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.